The National Eye Institute of the National Institutes of Health (NIH) has awarded Small Business Innovation Research (SBIR) grant R43-EY037590 to Proteris Biotech, Inc. (PB) to continue preclinical development of an innovative eye drop technology for the treatment of dry eye. The ultimate goal is a new U.S. Food and Drug Administration (FDA)-approved biologic drug.
The National Eye Institute of the National Institutes of Health (NIH) has awarded Small Business Technology Transfer (STTR) grant R41-EY034396 to Proteris Biotech, Inc. (PB) to continue development of an innovative eye drop technology for the treatment of ocular surface damage in dry eye, also called epitheliopathy. The ultimate goal is a new U.S. Food and Drug Administration (FDA)-approved biologic drug. The grant begins September 30, 2023.
The National Eye Institute of the National Institutes of Health (NIH) has awarded a Small Business Technology Transfer (STTR) grant R41-EY025890 to Proteris Biotech, Inc. (PB) to develop innovative technology for the treatment of dry eye. The ultimate goal is a new U.S. Food and Drug Administration (FDA) approved biotherapeutic called Protearin. The grant will begin May 1, 2016.
A natural protein in tears could help researchers looking at the common affliction.
Researchers find natural protein seals ocular surface and offers promise to ameliorate dry eye.
